Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1721-1730 of 2762 for cancer

Edit search filters
  1. Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

    Rochester, MN

  2. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation

    Rochester, MN

  3. Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  4. Feasibility of Mobile Physical Activity Monitoring Devices in Urology

    Rochester, MN

  5. Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study to Assess the Safety and Preliminary Effectiveness of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Rochester, MN

  7. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

    Rochester, MN

  9. A Study of the Safety And Effectiveness of Palbociclib Plus Cetuximab versus Cetuximab Alone to Treat Head and Neck Cancer

    Rochester, MN

  10. A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer